Mind Medicine (MindMed) I...

5.55
-0.42 (-7.04%)
At close: Apr 03, 2025, 3:59 PM
5.62
1.17%
After-hours: Apr 03, 2025, 07:51 PM EDT
-7.04%
Bid 5.51
Market Cap 418.67M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -1.54
PE Ratio (ttm) -3.61
Forward PE -4.85
Analyst Buy
Ask 6.97
Volume 1,305,047
Avg. Volume (20D) 1,998,208
Open 5.62
Previous Close 5.97
Day's Range 5.43 - 5.75
52-Week Range 5.03 - 12.22
Beta 2.40

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has com...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 15, 2016
Employees 74
Stock Exchange NASDAQ
Ticker Symbol MNMD
Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for MNMD stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 260.04% from the latest price.

Stock Forecasts
2 months ago
+7.68%
Mind Medicine shares are trading higher after Ever... Unlock content with Pro Subscription
4 months ago
+5.65%
Mind Medicine shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.